EnteroMedics' vBloc® Neurometabolic Therapy Featured on "The Doctors" TV Show

ST. PAUL, Minn., March 13, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its vBloc^® Neurometabolic Therapy for the treatment of obesity will be featured on the March 14 episode of the Emmy Award-winning syndicated daytime talk show The Doctors. Frank Chae, MD, FACS, Chief Surgeon and Head of the Bariatric Center at Sky Ridge Medical Center in Colorado and Cindy Hudak, one of his patients who received vBloc Therapy will discuss the benefits of vBloc Therapy and Cindy's personal story of battling obesity. The Doctors, on air since 2008, offers the most timely, topical and practical health, wellness and lifestyle information on daytime television. To find a station where The Doctors airs, please visit http://photos.thedoctorstv.com/when-its-on/

"The Doctors is a well-respected television show many people watch in order to learn about different medical conditions, including obesity, and the latest innovative treatments available to them," said Dan Gladney, EnteroMedics President, Chief Executive Officer and Chairman of the Board. "We are thrilled The Doctors has decided to feature vBloc Therapy and hope patients who see the segment and are appropriate for its use will take action and contact their doctor to learn more about its benefits. I also want to applaud vBloc patient Cindy Hudak for her great success to date and thank her for sharing her story."

vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m², or a BMI of 35 to 39.9 kg/m² with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea who have had a poor response to trying to lose weight under supervision in the last 5 years.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc^® Neurometabolic Therapy, delivered by a pacemaker-like device called the vBloc^® System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' vBloc^® System has received U.S. Food and Drug Administration approval and CE Mark.

Information about the vBloc^® System and vBloc^® Neurometabolic Therapy

You should not have an implanted vBloc^® System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the vBloc System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.

Talk with your doctor about the full risks and benefits of vBloc Therapy and vBloc System. For additional prescribing information, please visit www.enteromedics.com.

If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.vbloc.com or call 1-800-MY-VBLOC.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc^® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc^® System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc^® System; physician adoption of our vBloc^® System and vBloc^® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 8, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE EnteroMedics Inc.

Related Links

http://www.enteromedics.com